Net-remission rates of biologics and small molecules in ulcerative colitis: A systematic review and network meta-analysis. (Embase).

Abstract

Abstract Eligible RCTs examined the efficacy of biological therapies (anti-TNFα antibodies (infliximab, adalimumab, or golimumab, certolizumab), anti-integrin antibodies (vedolizumab or etrolizumab), or anti-interleukin-12/23 antibodies (ustekinumab)) or small molecules (janus kinase inhibitors (tofacitinib, filgotinib, or upadacitinib) or sphingosine-1-phosphate receptor modulators (ozanimod)) at the doses taken through into testing in phase III clinical trials. The first period of any cross over study were also eligible. For induction of remission, trials had to report one or more of the following endpoints: a composite of clinical and endoscopic remission; clinical remission; endoscopic remission; or histological remission. To be considered as induction remission, duration of therapy was 10 weeks or less and greater than 10 weeks for maintenance remission. The maintenance period was at the end of 52 weeks where we required the reporting of at least one of the endpoints of the induction arm. The study had to report both induction and maintenance data for same cohort for patients.